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1. Introduction 
Cryptococcosis is a systemic disease caused by the yeast Cryptococcus spp. Cryptococcus 
neoformans and C. gattii are the etiological agents of fungal meningoencephalitis. Chronic 
meningitis is the most common clinical presentation of cryptococcosis. In contrast with the 
acute meningitis, patients with chronic meningitis develop an indolent course of symptoms 
for at least four weeks like headache, nausea, decreased memory and comprehension. 
Cerebral cryptococcomas can also cause significant neurological morbidity, and these mass 
lesions require relief of increased intracranial pressure and prolonged antifungal therapy. 
Although cryptococcosis is considered one opportunistic infection of the central nervous 
system and lungs, extra neural and non-pulmonary forms may be found. The disease is 
almost always associated with impaired immunity, and occurs in patients with lymph 
proliferative disorders, steroid therapy and organ transplantation. Before the acquired 
immune deficiency syndrome (AIDS) the cases with cryptococcosis were sporadic. Despite 
of the highly active antiretroviral therapy-HAART, acute mortality due to HIV-associated 
cryptococcal meningitis remains unacceptably high (Lortholary et al., 2006), and 
consequently, this disease remains a leading cause of death in Africa, Asia, and Brazil 
(French et al., 2002; Vidal et al., 2008; Pappalardo et al., 2009). 
Cryptococcosis has been documented in few (~3%) of solid-organ transplant recipients with 
68% of the cases occurring one year after transplantation., and almost half cases have 
pulmonary cryptococcal infection. The disease is limited to the lungs only in 6% to 33% of 
cases, although cryptococcal meningitis and disseminated infections have been documented 
in up to 60% of patients (Husain et al., 2001; Vilchez et al., 2002; Singh et al., 2007; Shaariah 
et al., 1992). Data on non-transplant patients or presumably immunocompetent hosts 
presenting cryptococcal meningitis are scarse, because the majority of patients prior to the 
HIV epidemic were significantly immunosuppressed, receiving steroids or having cancer or 
other degenerative diseases (Perfect et al., 2010).  
2. Cryptococcosis and AIDS  
Cryptococcus neoformans is yeast with a tropism for the central nervous system, and 70-90% 
of infections caused by this species manifested as meningitis, after spores inhalation and 
hematologic dissemination. Meningitis is frequently associated to the pulmonary form. In 
immunosuppressed patients with pulmonary cryptococcosis, meningitis should be always 
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ruled out by lumbar puncture (Mitchell & Perfect, 1995). Cryptococcal meningitis is a 
common and often fatal opportunistic infection in HIV-infected patients, especially in 
developing countries and in patients with CD4 cells < 100/µL. Incidence of cryptococcosis 
decreased in the era HAART, but the incidence and mortality of the disease are still high in 
some areas of the world. Recent review suggests that there are ~1 million new cases and at 
least 500.000 annual deaths world-wide due to HIV-associated cryptococcosis (Park et al., 
2009).  
Computed tomography or magnetic resonance imaging head scans should be done in all 
patients prior to any diagnostic or therapeutic lumbar puncture, with focal neurological 
signs or impaired mental functions. Patients with HIV disease generally do not have 
hydrocephalus or cryptococcal mass lesions and these exams commonly are normal or show 
cerebral atrophy without obstruction or other abnormality (Graybill et al., 2000). 
The most common signs and symptoms are headaches, fever, nausea, vomiting, lethargy, 
coma, memory loss over 2 to 4 weeks; however, sometimes patients only refer general 
bodily discomfort. Patients can also present with pulmonary or cutaneous manifestations 
with or without apparent neurologic disease (Perfect et al., 2010). 
The diagnosis of the meningeal cryptococcosis through mycological procedures is easy and 
based on the visualization of encapsulated yeast cells in the cerebral spinal fluid specimen, 
and immunological assays. If cryptococal meningitis is confirmed, extra neural sites should 
be discharged by means of screening of cutaneous lesions, procedures for blood cultures, 
examination of urine, pleural fluid, sputum, prostatic fluid, and others clinical specimens for 
detect the etiological agent..  
Antifungal drugs more commonly used for treat cryptococcal meningitis are amphotericin B 
deoxycholate, amphotericin B lipid complex or liposomal formulation, flucytosine, and 
fluconazole (Perfect et al., 2010). Ideally, antifungal therapy should rapidly sterilize the 
central nervous system and this should be the primary focus of any induction strategy 
(Bicanic et al., 2007). The antifungal therapy in cryptococcal meningitis in AIDS patients is 
divided into 3 phases: induction (for at least 2 weeks), consolidation (for a minimum of eight 
weeks) and maintenance or suppression phase.  
The induction phase aims the achievement of sterilization of cerebral spinal fluid, or 
reduction of fungal burden. The consolidation phase warrants maintenance of negative 
cultures and normalization of clinical parameters. Some experts and guidelines suggest a 
routine lumbar puncture at the second week, with prolongation of the induction phase if the 
cerebrospinal fluid culture is not yet sterile. The drug of choice for induction is amphotericin 
B (0,7-1,0 mg/kg per day intravenously), and fluconazole is the choice for consolidation [400 
mg (6 mg/kg) per day orally]. Fluconazole should be introduced for consolidation regimen 
whenever the mental status recovered, fever, headache and meningeal symptoms disappear, 
and/or yeast culture results are negative at the second week. Despite the theoretic 
antagonism between amphotericin B and fluconazole, most animal model data suggests that 
both drugs together are a very effective combination against C. neoformans (Menichetti et al., 
1996; Larsen et al., 2004; Larsen et al., 2005; Pappas et al., 2009; Perfect et al., 2010).  
Maintenance therapy should be initiated after completion of primary therapy with an 
induction and consolidation regimen, and continued until there is evidence of persistent 
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immune reconstitution with successful HAART. Since a cure doesn’t exist in AIDS patients, 
maintenance should be done for at least one year with 200 mg/daily of fluconazole 
(standard for consolidation and maintenance), with CD4 cell count > 100 cells/µL and 
undetectable or very low HIV RNA level sustained for >3 months (minimum of 12 months 
of antifungal therapy). Itraconazole is an alternative, albeit less effective, choice for 
maintenance therapy. Oral itraconazole if patient is intolerant of fluconazole, may be 
administered (200 mg per day or a higher dosage 200 mg twice per day orally) (Denning et 
al, 1989).  
The management of cryptococcosis is difficult, particularly in some developing countries 
where flucytosine is no more commercialized and liposomal or lipid complex amphotericin 
B formulations are not affordable. The nephrotoxicity of amphotericin B deoxycholate 
represents a big challenge for the physicians in such regions (Sharkey et al., 1996). 
Furthermore the treatment of increased intracranial pressure represents another serious 
issue since approximately one-half of HIV-infected patients have elevated baseline opening 
intracranial pressures requiring drainage of cerebral spinal fluid daily (Bicanic et al., 2009). 
Medications other than antifungal drugs are not useful in the management of increased 
intracranial pressure in cryptococcal meningoencephalitis (Perfect et al. 2010).  
The rapid clearance of infection by sterilization of cerebrospinal fluid associated with 
clinical improvement on day 14 of treatment is predictive of a good evaluation in the 10th 
week (Robinson et al., 1999). The rate of clearance of cryptococcal colony-forming units is a 
clinically meaningful endpoint. Maybe deaths within two weeks are nearly all related to 
cryptococcal infection, whereas, after this time, deaths are increasingly related to other 
complications of late-stage HIV infections or extended hospitalization (Bicanic et al., 
2009). The good control of elevated CSF pressure and symptoms are very important, and 
they are some of the most critical determinants in the outcome of cryptococcal meningitis 
(Perfect et al., 2010). This elevated CSF pressure level is generally linked to a high burden of 
yeast in the cerebrospinal fluid (Bicanic et al., 2009). Factors that indicate a bad outcome in 
cryptococcal meningitis include abnormal mental status, poor host inflammatory response 
(cerebrospinal fluid white cells <20/mL), raised CSF opening pressure (> 25 cm H2O), high 
organism burden, extra neural sites and the lack of effective antifungal treatment. Some 
studies confirm the greater fungicidal activity of amphotericin B plus flucytosine to improve 
prognosis (Brouwer et al., 2004). 
Potential complications in management of cryptococcal infection, includes increased 
intracranial pressure, immune reconstitution inflammatory syndrome, drug resistance, and 
cryptococcomas. Opportunistic infections such bacteremia, toxoplasmosis, histoplasmosis, 
or oropharingeal candidosis, tumors, drug-related complications may occur in heavily 
immunocompromised patients. Moreover, the long-time of hospitalization, never less than 
two weeks, increased the risk for hospital infections Development of classic hydrocephalus 
later during treatment and follow-up can occur. Furthermore, impaired vision, mental 
deficit and cranial nerve palsies are described sequels of cryptocccosis.  
After discontinuation of maintenance therapy, relapses with positive culture result may 
occur and so careful follow-up of patients is necessary. Patients will need follow-up lumbar 
punctures and intracranial pressure should be measured. Reinstitution of fluconazole 
maintenance therapy should be considered if the CD4 cell count decreases to <100 cells/mL 
and/or the serum cryptococcal antigen titer increases [Zolopa et al., 2009) 
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2.1 Cryptococcosis and IRIS  
Immune reconstitution inflammatory syndrome (IRIS) consists of clinical manifestations 
compatible with enormous tissue inflammation in patients with rapid improvement in 
cellular immunity and worsening in central nervous system signs and/ or symptoms of the 
disease. About 30% of patients with cryptococcal meningitis will develop IRIS when 
HAART is initiated (Bicanic et al., 2006; Antinori et al., 2009). Perfect et al. (2010) suggest a 
wide range of two to ten weeks after initiation of cryptococcosis therapy to introduce 
HAART. The exact moment to start HAART in patients with cryptococcal meningitis to 
avoid immune reconstitution inflammatory syndrome, is still uncertain. 
3. Etiologic agents 
Cryptococcus neoformans and Cryptococcus gattii cause nearly all human and animal 
cryptococcal infections. In addition to these common species, there are nearby 15 other 
members of this genus which have appeared as human clinical isolates, such as C. laurentii, 
C. luteolus (80% of non-neoformans and non-gattii cases), C. albidus, C. diffluens, and C. 
uniguttulatus (Heitman et al. 2011). Cryptococcus gattii can be discerned from C. neoformans 
using a wide range of microbiological and molecular techniques. A simple and classical 
method is the use of canavanine-glycine-bromothymol blue (CGB) medium, which allows C. 
gattii but not C. neoformans to grow changing the color medium from green-yellowish to 
blue. Molecular approaches yield determine distinct genotypes among the species. 
Polymerase chain reaction (PCR) fingerprinting, restriction fragment length polymorphism 
(RFLP), analysis of specific loci, and amplified fragment length polymorphism (AFLP) 
fingerprint analysis, and multi-locus sequence typing scheme (Meyer et al., 2009) are 
molecular tools (Meyer et al., 2009). Furthermore, interspecies hybrid forms have been 
isolated from clinical samples, and they seem to present a higher virulence potential than 
regular C. gattii or C. neoformans isolates (Boekhout et al., 2001).  
The species differs in many aspects and improved surveillance should enable better 
assessment of the local incidence of these two species and also clinical manifestation and 
course associated to each species. Whereas C. neoformans primarily affects persons infected 
with human immunodeficiency virus worldwide, C. gattii primarily affects HIV-uninfected 
persons in tropical and subtropical regions (Pappalardo and Melhem, 2003; Chaturvedi et al, 
2005; Martins et al., 2007; Heitman et al. 2011).  
It noteworthy the emergence of C. gattii in temperate climate regions that suggests the 
pathogen might have adapted to a new climatic niche or that climatic warming might have 
created an environment for spore survival and propagation of this species. Cryptococcus 
gattii is more likely to cause cryptococcomas, and seems to be less responsive to antifungal 
drugs (Gomez-Lopes et al., 2008).  
The profile of antifungal susceptibility can be assessed through in vitro antifungal 
susceptibility testing. Performance of these tests may help not only to monitor the 
development of resistance in Cryptococcus isolates, but could also determine the best 
antifungal therapy, predicting possible failures due to a resistant strain. Antifungal 
susceptibility testing is indeed a recognized useful tool to aid the treatment of Candida 
infections. References broth microdilution methods for this genus are described in 
document M27-A3 of the Clinical and Laboratory Standards Institute – CLSI, and in the doc. 
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E.Def 7.1 of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
(CLSI, 2008, Subcommittee on Antifungal Susceptibility Testing of the ESCMID, 2008). 
Although the reference methodologies of CLSI and EUCAST are different, the results are 
very similar and results are comparable. 
Determination of resistance in isolates of Cryptococcus, quite distinct yeast in which 
fermentation is absent, the micro dilution methods present some technical problems. The 
most relevant one is the low growth of Cryptococcus strains due to the oxygen limited 
environment found in the microdilution plates. So, the standard methods developed for 
Candida are not still completely reliable for test Cryptococcus isolates and efforts have been 
made toward standardization of antifungal susceptibility testing of Cryptococcus and other 
non-fermentative yeasts (Zaragoza et al., 2011).  
The minimum inhibition concentration (MIC) of antifungal drugs against clinical and 
environmental Cryptococcus strains has been extensively studied. Cryptococcus neoformans has 
been more frequently assessed for its in vitro susceptibility to a wide variety of antifungal 
compounds, including the new triazoles posaconazole, voriconazole, ravuconazole, and 
isavuconazole. Otherwise, few studies using relatively small sets of C. gattii isolates have 
been performed to investigate their in vitro susceptibilities to these drugs. Since fluconazole 
may last for a very long period of time, development of resistance to this agent has been 
reported both in vivo and in vitro. Many studies pointed out a significant emergence of 
clinical isolates of C. neoformans which present high fluconazole-MICs (MIC >4 mg/L) in 
different geographical regions (Aller et al., 2000; Dias et al., 2006; Pfaller et al, 2004). 
Resistance to fluconazole or to other azole compounds is not a cause of concern in the 
continent of America, where 3% to 10% of strains present high MIC. On opposite, the data 
from African, Cambodian and Spanish C. neoformans isolates showed high fluconazole-MICs 
(Bicanic et al., 2006; Perkins at al., 2005; Pfaller et al, 2004; Sar et al., 2004). It should be also 
pointed out that some authors did not find any correlation with clinical failure and the in 
vitro MIC data (Dannaoui et al., 2006). Therefore, the interpretation of the data is quite 
difficult since there are not interpretative clinical breakpoints for distinguish between 
resistant or susceptible Cryptococcus isolates that could predict failure or clinical success. 
However, breakpoints have not been defined yet, it is worth performing antifungal 
susceptibility testing against sequential isolates obtained from patients under antifungal 
therapy. An increased in MICs values during the monitoring could predict development of 
resistance of the original strain resulting in therapeutic concerning. Moreover, 
heteroresistance to fluconazole in C. neoformans or C. gattii is a phenomen that could play a 
role in clinical failure (Mondon et al., 1999; Varma, and Kwon-Chung, 2010). 
The identification of amphotericin B resistant organisms seems to be more difficult however, 
as reference methods fail to detect it and trustworthy comparisons have not been done. 
Consistent detection of AMB resistance in vitro in Cryptococcus neoformans has proven 
difficult, and few studies demonstrated that majority of the initials isolates are susceptible to 
the polyene (Lozano-Chiu et al., 1998; Rodero et al., 2000a). Time-kill curves, a methodology 
to measure the fungicidal activity of amphotericin B, have been evaluated to identify 
resistance or tolerance to this antifungal agent in Cryptococcus isolates (Rodero et al., 2000b). 
Yeast isolates with amphotericin B MICs 2 mg/L are extremely uncommon, and therefore 
any strain with a MIC > 2 mg/L should be considered as potentially resistant to this polyene 
(CLSI, 2008). 
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4. Laboratory identification of cryptococcus in a routine clinical laboratory 
The distinguishing feature of Cryptococcus genus is a polysaccharide capsule, and techniques 
that detect this cryptococcal structure and its components are the most useful tools as 
diagnostic tests. Evaluation of spinal fluid is essential in diagnosing central nervous system 
disease. The yeast cells of Cryptococcus are spherical in shape and approximately 5 to 7 µm in 
diameter while the capsules vary enormously in their thickness and are of a few 
micrometers of average. A rapid, simple and inexpensive procedure employs India ink 
staining to detect the encapsulated cells of Cryptococcus in pellets from centrifuged 
cerebrospinal fluid and other specimens. The lower limit of detection of India ink is ~103 to 
104 yeast cell/ml. Disadvantages include the poor sensitivity of the technique in diagnosing 
cryptococcal meningitis in non-HIV-infected patients (30 to 72%) compared with culture. 
The sensitivity of India ink in high (~80%) for patients with overwhelming infection such 
HIV-infected patients (Kwon-Chung and Bennett, 1992; Heitman et al. 2011). 
False-positive results can occur if inexperienced readers interpret lymphocytes or fat 
droplets as fungal cells. The capsular polysaccharide antigen that can be detect using 
commercial systems and represents the most valuable rapid test for the laboratory diagnosis 
of cryptococcosis. During infection, the capsular antigen is solubilized in cerebrospinal fluid, 
serum, urine and fluid recovered from the lungs. Almost all high fungal burden patients 
will have a positive serum and cerebrospinal fluid. Commercial kits typically demonstrate 
90 to 100% sensitivity and 97 to 100% specificity for cerebrospinal fluid compared with 
culture and clinical diagnosis. However, in patients without AIDS the sensitivity of serum 
cryptococcal antigen in diagnosing cryptococcal meningitis is ~60%. The level of detection of 
most kits is at least 10 ng of antigen/ml. The most common testing format to detect antigen 
is latex agglutination assay. Moreover, antigen detection can be quantitative as the greatest 
dilution of the fluid that gives a positive result. Uncommon false-positive results can be 
encountered, particularly in serum contaminated with syneresis fluid, in presence of 
rheumatoid factor. In addition, false-positive results can occurs in patients with collagen 
vascular disease, chronic meningitis, malignancy (<0.3%), or even presenting a yeast 
infection caused by Trichosporon. Many kits include an enzymatic or heat pre-treatment in 
order to minimize the false-positive results, and incorporate a control reagent. In cases in 
which physicians doubt a positive results, they may ask the laboratory personal to treat the 
specimen with 2,β-mercaptoethanol, as it eliminates non-specific reactions. False-negative 
results were described in low organism burden infections and for capsule-deficient 
Cryptococcus. The latex assay also yields false-negative reactions due to a prozone effect that 
can be improved by specimen serial dilutions. An enzyme immunoassay is also available to 
detect glucuronoxylomannan, the principal polysaccharide component. The enzymatic assay 
it is slightly more sensitive than latex assay; similar to latex test, false-positive and false-
negative results can occur (Kwon-Chun et al, 1981). 
Measuring capsular antigen titers in serial clinical specimens for monitoring cerebrospinal 
fluid or serum cryptococcal antigen levels is useful in the management of cryptococcosis in 
non-AIDS patients. Decrease in antigen titers has limited value in the management of 
meningitis in such cases. Although it is expected that the titers should change after a few 
weeks of therapy, there is no evidence that titers predict or correlate with clinical and 
mycological outcomes (Kwon-Chung and Bennett, 1992).  
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The commercial (1,3) β-D-glucan assay detects a polysaccharide component of the cell wall 
of several pathogenic fungi, but given the limited experience to date with this test in 
cryptococcosis cases, there is no recommendation of using this test in the diagnosis of 
cryptococcosis. 
Histological stains for tissue sections for revel Cryptococcus cells includes Gomori 
methenamine silver and calcofluor white, that are broad-spectrum fungal histochemical 
stains for fungi regardless of type. The best histological procedure uses mucicarmine, alcian 
blue, and periodic acid-Schiff that stain the capsule and Fontana-Masson stain, which 
interacts with the cell wall.  
Culture techniques will remain the mainstay of the diagnosis of this infection. Culturing for 
Cryptococcus may be appropriate, even when the CSF profile is unremarkable. Blood, CSF, 
urine, and other clinical specimens should be cultured for fungi. Yeasts cells growth in 2 to 7 
days in classical Sabouraud dextrose agar, typically as brilliant, mucous, pale colored 
colonies. Besides de capsular cell, one of the defining characteristics of Cryptococcus 
neoformans and C. gattii is its ability to synthesize a dark cell wall-associated pigment 
(melanin) when grow in media containing phenolic compounds, such Birdseed agar. 
Identification based on conventional biochemical and physiological assays, which are 
routinely used in a clinical laboratory for yeasts, can be difficult or even impossible for 
conclusive identification of Cryptococcus species. Laboratories should recognize that C. gattii 
cannot be differentiated from C. neoformans by conventional laboratory methods. C. gattii can 
only be differentiated from C. neoformans by specific biochemical or molecular testing. 
Laboratories should seek for definitive identification at an appropriate reference laboratory. 
5. Conclusion 
In conclusion, cryptococcosis remains a challenging management issue around the world 
and all patients presenting symptomatic increased intracranial pressure should be tested for 
HIC-infection, and screened for cryptococcal meningitis for receive early antifungal therapy. 
Relapses of symptoms and signs can occur during or after treatment and patients should be 
monitored for IRIS, drug resistance or compliance issues.  
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